#USA #New Orleans #Nordic Pharma #LACRIFILL #SEVER Life Sciences

Nordic Pharma to Showcase LACRIFILL® Canalicular Gel at AAO 2026

Nordic Pharma, Inc., a subsidiary of SEVER Life Sciences B.V., will prominently feature the LACRIFILL® Canalicular Gel during the American Academy of Ophthalmology Annual Meeting scheduled for October 9-12, 2026, in New Orleans, Louisiana. This innovative gel aims to control ocular surface conditions and enhance patient care post-surgery.

Having gained traction in over 2,200 ophthalmology and optometry practices across the United States, LACRIFILL Canalicular Gel is now a go-to product for patients who have undergone cataract or refractive surgeries. More than 130,000 patients have reportedly benefited from this groundbreaking therapy, which not only alleviates symptoms of dry eye disease but also reduces the dependence on traditional eye drops.

In a recent patient experience survey, an impressive 96% of respondents who had cataract surgery in the last six months, and 91% of all surveyed patients, expressed that LACRIFILL made their eyes feel significantly better. This statistic underscores the potential of LACRIFILL as a transformative solution in ophthalmology.

Jai G. Parekh, M.D., MBA, the Chief Commercial Officer of Nordic Pharma, emphasized the significance of sharing data at such a prestigious event: "The AAO provides an incredible platform to disseminate the latest advancements in the field of ophthalmology. We are eager to present research that substantiates the advantages of LACRIFILL Canalicular Gel, particularly its ability to offer improved comfort and stability in vision post-surgery and for those suffering from dry eye conditions."

The findings indicate a marked reduction in the need for both prescription and over-the-counter eye drops among patients dealing with dry eye disease. According to Dr. David Szynkarski of Mann Eye Institute in Houston, TX, "The critical control of the ocular surface after surgeries is essential for recovery and overall patient satisfaction. Our experience shows that 83% of patients who received LACRIFILL treatment reported less discomfort following their procedures. Given its indication for use of up to six months, LACRIFILL maintains its therapeutic benefits over an extended period."

At the AAO event, attendees will have the unique opportunity to observe eye care professionals administering LACRIFILL Canalicular Gel at the Nordic Pharma booth (#3136) on both Saturday, October 10, and Sunday, October 11, from 10 AM to 4 PM. Visitors will also have the chance to place product orders at the booth and engage in discussions about its application.

For more information on the LACRIFILL Canalicular Gel, including ordering details, potential users are encouraged to visit lacrifill.com.

About SEVER Life Sciences B.V.

SEVER Life Sciences is a global private specialty pharmaceutical holding company committed to enhancing quality of life worldwide. Based in the Netherlands, the organization comprises three complementary companies that focus on diverse pharmaceutical developments and technologies.

About Nordic Pharma, Inc.

Nordic Pharma, Inc., a subsidiary of SEVER Life Sciences B.V., collaborates with renowned global biopharmaceutical firms, leveraging its specialized knowledge in bringing medical devices and sterile manufacturing processes to the market.

This press release includes forward-looking assertions related to SEVER Life Sciences and Nordic Pharma’s strategic initiatives and potential developments. These statements involve risks and uncertainties that may result in actual outcomes differing considerably from those expressed. Factors influencing these results include general market conditions, evolving regulatory frameworks, the financial health of partners, and other variables affecting the business and financial performance of SEVER Life Sciences and Nordic Pharma.